Hospira

10 PBAC submissions on file, active 2008–2016. 70% have been recommended.

Drug portfolio

Sorted by PBS spend captured. PBS expenditure is credited to the sponsor with the most recent Recommended decision per drug, so biosimilars and originator brands aren't double-counted.

• Oxybutynin
  Urology · Recommended with restriction · 2023other sponsor
• Ibandronic acid
  Oncology · Recommended with restriction · 2008—
• Apomorphine hydrochloride
  Neurology · Recommended with restriction · 2018other sponsor
• Filgrastim
  Haematology · Recommended · 2018other sponsor
• Flucloxacillin
  Infectious disease · Recommended · 2015—
• Infliximab
  Rheumatology · Recommended with restriction · 2025other sponsor
• Pemetrexed
  Oncology · Recommended · 2023other sponsor

Therapy area mix

Activity by year

2008 (4) · 2009 (1) · 2010 (1) · 2014 (1) · 2015 (2) · 2016 (1)

Rejection patterns

Across 3 Not recommended decisions on file.

• 1×inadequate evidence that it is not inferior to the comparator clodronate
• 1×variability of evidence presented
• 1×errors in analysis of results
• 1×inappropriate indirect comparison methodology
• 1×heterogeneity in trial designs and exclusion criteria